ZIOP Insider Trading

Ziopharm Oncology Inc also files under TCRT; those filings are included.

Mixed · 180d
Open-Market Buys (180d)
$0
0 insiders
Open-Market Sells (180d)
$0
0 insiders
Net Insider Flow
$0
open market, 180d
Reporting Insiders
0
0 P/S transactions
Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Recent Form 4 Transactions

100 shown
DateInsiderRoleActionSharesPriceValue
Aug 6, 2026Weis HolgerCEOGrant(A)4K$2.01$9K
Jul 23, 2026Postma Robert WDirectorGrant(A)8K$1.92$16K
Jul 23, 2026Vieser JaimeDirectorGrant(A)9K$1.92$17K
Jul 23, 2026Weis HolgerCEOGrant(A)5K$1.92$9K
Jul 23, 2026Jerman Michael AllenDirectorGrant(A)8K$1.92$16K
Jun 30, 2026Weis HolgerChief Executive OfficerGrant(A)4K$2.26$9K
Jun 12, 2026Weis HolgerChief Executive OfficerGrant(A)8K$2.26$18K
May 22, 2026Weis HolgerChief Executive OfficerGrant(A)4K$2.37$9K
Apr 29, 2026Jerman Michael AllenDirectorGrant(A)6K$2.59$16K
Apr 29, 2026Postma Robert WDirectorGrant(A)6K$2.59$16K
Apr 29, 2026Vieser JaimeDirectorGrant(A)7K$2.59$17K
Jan 12, 2026Jerman Michael AllenDirectorGrant(A)5K$2.89$16K
Jan 12, 2026Vieser JaimeDirectorGrant(A)6K$2.89$17K
Jan 12, 2026Postma Robert WDirectorGrant(A)6K$2.89$16K
Nov 21, 2025Vieser JaimeDirectorGrant(A)5K$3.16$17K
Nov 21, 2025Postma Robert WDirectorGrant(A)5K$3.16$16K
Nov 21, 2025Jerman Michael AllenDirectorGrant(A)4K$3.16$13K
Aug 18, 2025Groenewald FerdinandVice President of FinanceGrant(A)11K$0
Aug 18, 2025Weis HolgerChief Executive Officer, DirectorGrant(A)14K$0
Aug 18, 2025Groenewald FerdinandVice President of FinanceGrant(A)4K$0
Jul 15, 2025Jerman Michael AllenDirectorGrant(A)10K$0
Jul 15, 2025Jerman Michael AllenDirectorGrant(A)3K$0
Jul 3, 2025Postma Robert WDirectorGrant(A)6K$0
Jul 3, 2025Vieser JaimeDirectorGrant(A)6K$0
Jul 3, 2025Vieser JaimeDirectorGrant(A)3K$0
Jul 3, 2025Postma Robert WDirectorGrant(A)4K$0
Jul 2, 2025Weis HolgerChief Executive Officer, DirectorGrant(A)130K$0
Jun 24, 2025Vieser JaimeDirectorBuy(P)250$4.49$1K
Jun 24, 2025Postma Robert WDirectorBuy(P)600$4.49$3K
Apr 13, 2025Postma Robert WDirectorGrant(A)21K$2.92$61K
Apr 13, 2025Postma Robert WDirectorGrant(A)21K$2.92$61K
Apr 13, 2025Vieser JaimeDirectorGrant(A)17K$0
Apr 13, 2025Weis HolgerDirectorGrant(A)11K$0
Apr 11, 2025Postma Robert WDirectorBuy(P)500$2.76$1K
Apr 11, 2025Postma Robert WDirectorBuy(P)500$2.76$1K
Mar 29, 2025Groenewald FerdinandVP, FinanceGrant(A)3K$0
Mar 29, 2025Lackey MelindaLegal & AdministrationGrant(A)1K$0
Mar 29, 2025Hogue Dale Curtis Jr.See Remarks, DirectorGrant(A)3K$0
Dec 31, 2024Vieser JaimeDirectorSell(S)818$2.00$2K
Dec 31, 2024Vieser JaimeDirectorSell(S)2K$2.01$4K
Aug 14, 2024Groenewald FerdinandVP, FinanceGrant(A)2K$0
Aug 14, 2024Lackey MelindaLegal & AdministrationGrant(A)2K$0
Jun 6, 2024Weis HolgerDirectorGrant(A)19K$0
Jun 6, 2024Vieser JaimeDirectorGrant(A)13K$0
Jun 6, 2024Postma Robert WDirectorGrant(A)13K$0
Jun 6, 2024Hofmeister RobertDirectorGrant(A)13K$0
Jun 6, 2024Weis HolgerDirectorGrant(A)5K$0
Jan 20, 2024Hogue Dale Curtis Jr.Interim CEO, DirectorGrant(A)600K$0
Dec 29, 2023Hogue Dale Curtis Jr.DirectorGrant(A)42K$0
Dec 29, 2023Hogue Dale Curtis Jr.DirectorGrant(A)150K$0
Sep 1, 2023Boyle Kevin S. Sr.Chief Executive Officer, DirectorSell(S)68K$0.14$10K
Jun 6, 2023Postma Robert WDirectorGrant(A)100K$0
Jun 6, 2023Hofmeister RobertDirectorGrant(A)100K$0
Jun 6, 2023Thistle MaryDirectorGrant(A)100K$0
Jun 6, 2023Huang JamesDirectorGrant(A)100K$0
Jun 6, 2023Vieser JaimeDirectorGrant(A)100K$0
Jun 6, 2023Weis HolgerDirectorGrant(A)100K$0
Mar 30, 2023Hofmeister RobertDirectorGrant(A)150K$0
Mar 30, 2023Hofmeister RobertDirectorGrant(A)17K$0
Mar 15, 2023Lackey MelindaSee RemarksGrant(A)200K$0
Mar 15, 2023Srivastava Abhishek KSee RemarksGrant(A)125K$0
Mar 15, 2023Wong MichaelVice President, FinanceGrant(A)125K$0
Mar 15, 2023Boyle Kevin S. Sr.Chief Executive Officer, DirectorGrant(A)1.8M$0
Mar 15, 2023Deniger DrewSee RemarksGrant(A)125K$0
Nov 29, 2022Postma Robert WDirectorBuy(P)750K$0.65$488K
Nov 29, 2022Vieser JaimeDirectorBuy(P)1.3M$0.65$813K
Sep 15, 2022Deniger DrewVP, Research and DevelopmentGrant(A)305K$0
Sep 15, 2022Wong MichaelVP, FinanceGrant(A)50K$0
Sep 15, 2022Srivastava Abhishek KSee RemarksGrant(A)25K$0
Sep 15, 2022Lackey MelindaSenior Vice President, LegalGrant(A)185K$0
Aug 30, 2022Boyle Kevin S. Sr.Chief Executive Officer, DirectorTax withholding(F)19K$2.41$45K
Aug 12, 2022Srivastava Abhishek KSee RemarksGrant(A)250K$0
Jun 22, 2022Thistle MaryDirectorGrant(A)40K$0
Jun 22, 2022Huang JamesDirectorGrant(A)100K$0
Jun 22, 2022Thistle MaryDirectorGrant(A)100K$0
Jun 22, 2022Huang JamesDirectorGrant(A)80K$0
Jun 22, 2022Postma Robert WDirectorGrant(A)100K$0
Jun 22, 2022Postma Robert WDirectorGrant(A)40K$0
Jun 22, 2022Thistle MaryDirectorGrant(A)100K$0
Jun 22, 2022Thistle MaryDirectorGrant(A)40K$0
Jun 22, 2022Huang JamesDirectorGrant(A)100K$0
Jun 22, 2022Huang JamesDirectorGrant(A)80K$0
Jun 22, 2022Postma Robert WDirectorGrant(A)100K$0
Jun 22, 2022Postma Robert WDirectorGrant(A)40K$0
Jun 22, 2022Vieser JaimeDirectorGrant(A)100K$0
Jun 22, 2022Vieser JaimeDirectorGrant(A)40K$0
Jun 22, 2022Bowden ChristopherDirectorGrant(A)100K$0
Jun 22, 2022Bowden ChristopherDirectorGrant(A)40K$0
Jun 22, 2022Weis HolgerDirectorGrant(A)100K$0
Jun 22, 2022Weis HolgerDirectorGrant(A)40K$0
Mar 30, 2022De Groot EleanorEVP, OperationsGrant(A)350K$0
Mar 30, 2022Boyle Kevin S. Sr.Chief Executive Officer, DirectorGrant(A)2.0M$0
Dec 22, 2021De Groot EleanorEVP, OperationsSell(S)20K$1.27$26K
Dec 10, 2021Lackey MelindaSenior Vice President, LegalGrant(A)370K$0
Nov 17, 2021Boyle Kevin S. Sr.Chief Executive Officer, DirectorBuy(P)9K$1.40$13K
Nov 16, 2021Boyle Kevin S. Sr.Chief Executive Officer, DirectorBuy(P)884$1.40$1K
Sep 29, 2021Vieser JaimeDirectorBuy(P)100K$1.91$191K
Sep 2, 2021Postma Robert WDirectorBuy(P)54K$1.73$94K
Sep 2, 2021Hagen HeidiDirectorBuy(P)24K$1.76$42K
Sep 2, 2021Postma Robert WDirectorBuy(P)21K$1.73$35K

Data Source

Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.

Issuer: Ziopharm Oncology Inc, SEC CIK 0001107421. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ZIOP and shows every filing by that issuer (also filed as TCRT).

Coverage: Form 4 filings indexed 2006-01-022026-09-09. Earlier history is backfilling; this window widens as it deepens.

Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).